Korro Bio, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Korro is an early-stage biopharmaceutical company developing RNA-editing medicines. The November 2023 reverse merger means the historical financial statements reflect Legacy Korro; per-share comparisons are affected by the substantially different share counts between periods.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue from product sales | None | None; no product candidates approved for sale |
| Research and development expense | $13.6 million | $14.7 million; down $1.1 million |
| General and administrative expense | $7.9 million | $5.4 million; up $2.5 million |
| Total operating expenses | $21.5 million | $20.1 million; up $1.4 million |
| Other income, primarily interest | $1.9 million | $0.5 million |
| Net loss | $19.6 million | $19.6 million; essentially unchanged |
| Basic and diluted loss per share | $2.44 | $72.20; share-count change makes comparison less meaningful |
| Net cash used in operating activities | $21.9 million | $19.7 million |
| Capital expenditures | $5.6 million | $1.5 million |
Balance sheet at March 31, 2024: Cash and cash equivalents were $138.8 million; restricted cash was $7.0 million. Total assets were $198.0 million, total liabilities $46.6 million, and stockholders’ equity $151.4 million. The filing reports no conventional borrowings; liabilities include $35.9 million of operating lease obligations.
Accumulated deficit was $202.6 million. The company remains loss-making, with no meaningful product-sales margins to report. Operating cash use increased by $2.2 million year over year, primarily due to $2.8 million of merger-related severance payments. Investing cash use was $5.6 million, principally reflecting property and equipment purchases. Q1 2023 investing cash flow included $17.0 million of investment maturities, and financing cash flow included $45.5 million of preferred-stock proceeds.
Material changes and financing
- R&D expense declined mainly because Q1 2023 included a $2.5 million upfront Genevant payment; lower lab supplies and consulting also contributed. Higher personnel and facilities costs partly offset the decline.
- G&A expense rose with personnel, professional services, facilities, IT and public-company costs.
- Interest income rose by $1.4 million year over year, reflecting higher interest rates and cash balances, helping keep net loss broadly unchanged despite higher operating expenses.
- After quarter-end, Korro closed a private placement on April 22, 2024, issuing 1,249,283 shares for approximately $70.0 million gross proceeds, before fees and expenses.
Outlook, risks and unusual items
- Management expects March 31 cash and cash equivalents plus the April PIPE proceeds to fund operating and capital needs into the second half of 2026. This estimate depends on assumptions that may prove incorrect. Separately, the financial-statement note says March 31 cash alone is expected to fund planned requirements for at least 12 months from issuance of the statements.
- The lead candidate, KRRO-110 for alpha-1 antitrypsin deficiency, remains in preclinical development. Korro cited a potential regulatory filing in the second half of 2024 and an anticipated interim clinical readout in the second half of 2025; no clinical trials had begun as of the filing.
- Management expects operating losses, negative operating cash flows and expenses to continue, including as development advances and public-company costs increase. Additional financing may be needed; equity financing could dilute shareholders, while other financing or collaboration arrangements could restrict operations or require relinquishing rights.
- RNA editing is novel and not clinically validated for human therapeutic use. Key risks include preclinical or clinical failure, regulatory uncertainty, manufacturing and delivery challenges, intellectual-property disputes, competition, and the need for substantial additional capital.
- The company has a long-term lease for its 60 First Street facility; disclosed future minimum lease payments were $68.2 million before the stated interest deduction, net of expected tenant-improvement allowance and rent credits. Two older facility arrangements were due to expire in 2024.
- A securities class action related to former Frequency Therapeutics disclosures was dismissed, but the plaintiff appealed; the First Circuit had not issued a decision. The company said it could not estimate a possible loss and had recorded no accrual.
- The merger-related contingent value rights liability and related MS asset-sale milestone asset were each valued at approximately $1.4 million at quarter-end. Progentos may owe future milestone payments of up to $17.5 million and a possible additional $0.7 million payment, subject to contractual conditions.
- Management reported disclosure controls and procedures were effective as of March 31, 2024, and no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Whether spending and development assumptions support the stated cash runway into the second half of 2026, and the net proceeds remaining from the April PIPE.
- Progress toward KRRO-110’s potential 2024 regulatory filing and 2025 interim readout, including any changes to timing or required studies.
- Future cash burn, capital spending, headcount and facility costs as the company advances toward clinical development.
- Potential dilution from outstanding options, warrants, equity plans and future financing; common shares outstanding were 8,022,463 at March 31 and 9,272,987 at May 9, 2024.
- Developments in the Frequency securities-litigation appeal, lease commitments, Genevant collaboration obligations and contingent MS-related payments.